Lendlease has announced, on Oct 7, that it will be commencing construction of a large-scale, greenfield vaccine facility in late 2021.
The move is said to be in support of Singapore’s growth as a life sciences hub.
The new facility will tap on Lendlease’s digital capabilities and best practices in construction, as well as its deep experience in the sector.
Lendlease has built the majority of Singapore’s major pharmaceutical facilities and over 90% of the biotechnology facilities in Singapore’s Tuas Biomedical Park.
See: Vaccine producers must step up
Beyond the vaccine facility, Lendlease has also been recently appointed to take on additional projects for its current clients in Singapore.
The works include expansion to existing facilities to enhance their capabilities.
“These project wins are a testament to Lendlease’s ability to deliver facilities with the highest standards of safety, quality and efficiency. We are humbled to be working alongside many of the world’s biggest pharmaceutical and biotechnology companies to help realise Singapore’s ambition to be the next-generation hub for life sciences,” says Ng Hsueh Ling, managing director, Singapore at Lendlease.
“The life sciences sector is one of our key focus areas, where we are looking to apply our expertise across the integrated real estate value chain. As we continue to expand our experience and elevate Lendlease’s life science integrated development capabilities, I am confident that Lendlease is well-poised in providing one of the best end-to-end solutions for future projects across Asia,” adds Justin Gabbani, CEO, Asia at Lendlease.